Check out the Pharma Exec Podcast of CEO Dr. Hanadie Yousef’s interview for the Emerging Pharma Leader award to learn more about what drives her ambitions for Juvena
Endpoints: CEO and co-Founder Dr. Hanadie Yousef is recognized by Endpoints for her lifelong scientific work and discoveries, for her entrepreneurship and business leadership as part of the 2023 “20 under 40” list of exceptional biotech leaders and global change makers
Juvena’s CEO and co-founder, Dr. Hanadie Yousef, was named among a distinguished short list of Emerging Pharma Leaders by Pharmaceutical Executive, which highlights her personal story and what drives Dr. Yousef’s passion for decoding secreted proteins for better human health
CEO Dr. Yousef joins the Biotech CEO sisterhood summit to cultivate a community of support for female-led biotech companies and mentorship. Discussions included CEO best practices, wellness, supporting women leaders, and board service. Learn more here where she is quoted.
As Juvena continues to welcome a tremendously talented team, we wanted to thank FierceBiotech, Endpoints News, STAT, Longevity.Technology, BioWorld, and BioCentury for highlighting Juvena Therapeutics’ expanded leadership team last week. Juvena is thrilled to have Neil Berkley as Chief corporate development officer, Mo Tabrizi PhD, RPh as VP of preclinical and non-clinical development, and Edward Moler, PhD as VP of data science. Juvena is looking forward to what’s ahead!
BioWorld Features Dr. Yousef’s and Dr. O’Connell’s founding story, showcasing Juvena’s proteomics platform to tackle chronic and age-related diseases by mining hESC-secreted proteins
Juvena’s Head of Data Science, Dr. Eddie Moler interviewed about his experiences in data science and AI applied to diagnostics and drug discovery and shares why he is excited about Juvena
